You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
McKinsey
Boehringer Ingelheim
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 6,444,878

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,444,878
Title: Method of plant selection using glucosamine-6-phosphate deaminase
Abstract:A selection method for selecting from a population of plant cells one or more genetically transformed plant cells is described. In the method, the population of plant cells includes selectable genetically transformed plant cells and possible non-transformed plant cells. Each of the selectable genetically transformed plant cells comprises a first expressible nucleotide sequence and optionally a second expressible nucleotide sequence. In the method, a component or a metabolic derivative thereof when present in a low concentration in a medium is a nutrient for both the selectable genetically transformed plant cells and the non-transformed plant cells. In the method, the component or the metabolic derivative thereof when present in a high concentration in a medium is toxic to the non-transformed plant cells. The first nucleotide sequence codes for a gene product having glucosamine-6-phosphate deaminase activity which is capable of converting the component or the metabolic derivative thereof when present in a high concentration in a medium to a nutrient for the selectable genetically transformed plant cells. The method includes the step of introducing the population of plant cells to a medium, wherein the medium includes a high concentration of the component or the metabolic derivative thereof. In the method, the component or the metabolic derivative thereof is a source of both carbohydrate and nitrogen for the selectable genetically transformed plant cells.
Inventor(s): Donaldson; Iain A. (Tinglev, DK), Bojsen; Kirsten (Allerod, DK), Jorgensen; Kirsten (Guldborg, DK), Jorsboe; Morten (Nykobing Falster, DK)
Assignee: Danisco A/S (Copenhagen, DK)
Application Number:09/367,293
Patent Claims:see list of patent claims

Details for Patent 6,444,878

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2017-02-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2017-02-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2017-02-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Merck
AstraZeneca
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.